Center of Excellence in Hepatitis and Liver cancer

Academic staffs
- Prof.Pisit Tangkijvanich, M.D.
- Assoc. Prof.Pongserath Sirichindakul, M.D.
- Asst. Prof.Nutcha Pinjaroen, M.D.
- Asst. Prof.Natthaya Chuaypen
- Asst. Prof.Chaiyaboot Ariyachet
- Prooksa Ananchuensook, M.D.
Description / Interest
The Center of Excellence in Hepatitis and Liver Cancer aims to be a leading entity in the field by focusing on cutting-edge research, innovative treatment methods, and academic excellence in combating liver disease and liver cancer. It strives to enhance understanding and treatment of liver diseases and cancer through biomarker studies, serving as a pivotal resource for academics and clinicians at both national and international levels. Additionally, it is dedicated to educating graduate students to cultivate new generations of researchers and clinicians, and to publishing significant research findings that advance the field.
Publications / innovations
- Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand (PLoS ONE, 2024, 19(3 March), e0300327)
- Gut Microbiota in Patients with Non-Alcoholic Fatty Liver Disease without Type 2 Diabetes: Stratified by Body Mass Index (Int J Mol Sci. 2024 Feb 2;25(3):1807.)
- ZNF469 is a profibrotic regulator of extracellular matrix in hepatic stellate cells (J Cell Biochem. 2024 May 5.)
- Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection (Sci Rep. 2023 Sep 2;13(1):14413.)
- First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection (J Hepatol. 2023 Nov;79(5):1139-1149.)
- Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma (Clin Gastroenterol Hepatol. 2024 Jan;22(1):72-80.e4.)
- Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial (Lancet Gastroenterol Hepatol. 2023 Sep;8(9):790-802.)
- Metabolic-Associated Fatty Liver Disease (MAFLD) is associated with immune activation, increased epicardial fat volume, and steatohepatitis among people with HIV in a Thai cohort HIV Med. 2023 Sep;24(9):1000-1012.)
- An innovative wireless electrochemical card sensor for field-deployable diagnostics of Hepatitis B surface antigen (Sci Rep. 2023 Mar 2;13(1):3523.)
Collaborations
International
- Department of Biomedical informatics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
- Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Molecular and Comparative Pathobiology, Jonhs Hopkins University
- Department of Biology, Gorge Mason University
- Beth Israel Deaconess Medical Center, Harvard Medical School
- Nanyang Technological University Singapore, Singapore
National
- Silpakorn University
- King Mongkut’s University of Technology Thonburi
- King Mongkut’s Institute of Technology Ladkrabang
- Mahidol University